Zhangzhou Pientzehuang Secures CDK4/6 Approval, Boosting China’s Oncology Landscape
Discover how Zhangzhou Pientzehuang’s new CDK4/6 inhibitor approval boosts its oncology portfolio, strengthens its market position, and fuels future growth in China’s pharma sector.
- ZHANGZHOU PIENTZEHUANG PHA-A
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read